News GSK’s Relvar Ellipta comes out on top in real world study Encouraging results will support growth of its next generation respiratory treatment
News AZ hopes to boost respiratory pipeline with Pieris deal AstraZeneca is hoping to boost its respiratory pipeline in a deal potentially worth more than $2 billion with US biotech Pieris Pharmaceuticals.
News GSK to search for blockbusters under new CEO Walmsley Big projects are priority as threat from generic Advair looms.
News AstraZeneca's Cambridge R&D site build running years late Building not operational until 2019, says CEO
News Circassia gives up on allergy treatments after second trial ... UK biotech to focus on respiratory drugs after house dust mite therapy fails.
News Boosted by new drugs, Boehringer shrugs off patent expiry BI boosted by new diabetes and respiratory drugs.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.